- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.8 Development and License Agreement Between the Registrant and Amgen, Inc.
- 10.32 Amended and Restated Agreement for the Sale and Assignment of Rights, Dated As of December 20, 2013, by and Between the Registrant and Drug Royalty L.P. 3.
- 10.33 Offer Letter of Susan Graf, Dated As of April 29, 2013
- 10.34 Contract Manufacturing and Supply Agreement, Dated As of September 7, 2012, by and Between Patheon Uk Limited and the Registrant, As Assignee of Takeda GMBH (F/k/a Nycomed Danmark Aps).
- 12 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32 Certification of Annual Financial Report by the Chief Executive Officer and Chief Financial Officer Furnished Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- PDF 10-K
- 12 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32 Certification of Annual Financial Report by the Chief Executive Officer and Chief Financial Officer Furnished Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NPS Pharmaceuticals, Inc.:
We consent to incorporation by reference in the registration statements (Nos. 333-79622, 333-17521, 333-124821, 333-168533, 333-188491, and 333-176012) on Form S-8 and (Nos. 333-146235 and 333-190494) on Form S-3 of NPS Pharmaceuticals, Inc. of our reports dated February 18, 2014, with respect to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2013, and the effectiveness of internal control over financial reporting as of December 31, 2013, which reports appear in the December 31, 2013 annual report on Form 10-K of NPS Pharmaceuticals, Inc.
/s/ KPMG LLP
Short Hills, New Jersey
February 18, 2014